🟢 Veradermics is trading 5% up in pre-market after VDPHL01 met all Phase 3 endpoints

Veradermics is trading at $128.54, up 5.12% in pre-market after announcing VDPHL01 met all primary and secondary endpoints in Phase 3 Study 304.

• Announced October 19, Study 304 involved 536 participants.
• Hair-count gains were 28.6 hairs/cm² with once-daily and 36.4 hairs/cm² with twice-daily dosing, versus 6.6 hairs/cm² for placebo.
• No treatment-related serious adverse events or cardiac events of special interest were reported; the announcement is the clearest company-specific catalyst for the pre-market gain.